A complicated Vogt-Koyanagi-Harada presenting with bilateral papillitis in a 5-year-old- case report.

IF 2.3 Q1 OPHTHALMOLOGY
Salem Almerri, Raed Behbehani
{"title":"A complicated Vogt-Koyanagi-Harada presenting with bilateral papillitis in a 5-year-old- case report.","authors":"Salem Almerri, Raed Behbehani","doi":"10.1186/s12348-025-00481-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We report a case of a 5-year-old patient with Vogt-Koyanagi-Harada presenting atypically with bilateral papillitis and refractory inflammation, leading to uveitic glaucoma and necessitating an escalation of adalimumab to 40 mg biweekly.</p><p><strong>Observations: </strong>A 5-year-old girl presented with a 3-week history of eye redness, excessive lacrimation, and photophobia. Her medical history was unremarkable. On examination, her best-corrected visual acuity (BCVA) were 20/80 and 20/100 in right and left eye, respectively, with normal intraocular pressure (IOP). Anterior segment examination revealed fine keratic precipitates, anterior chamber inflammation (+ 4 cells and flare), and semi-dilated pupils with posterior synechiae. Posterior segment evaluation was limited by severe vitritis. Laboratory investigations were unremarkable except for HLA-DR4, DR52, and DR53 positivity. Optical coherence tomography (OCT) of the optic nerve showed increased retinal nerve thickness. Initial treatment with corticosteroids and methotrexate failed to achieve remission. Attempts to taper corticosteroids resulted in recurrence of anterior chamber flare, prompting the introduction of adalimumab at 20 mg/biweekly. Despite relative stability, persistent anterior chamber inflammation and subsequent corticosteroid tapering led to the development of uncontrolled uveitic glaucoma requiring surgical peripheral iridectomy. Postoperatively, adalimumab was escalated to 40 mg/biweekly, enabling successful tapering of corticosteroids. Over a 9-month follow-up period, the patient remained flare-free, with BCVA improving to 20/20 in both eyes.</p><p><strong>Conclusions and importance: </strong>This case highlights an atypical presentation of VKH in a preschool-aged child, characterized by bilateral papillitis without exudative retinal detachment. Escalation of adalimumab to 40 mg biweekly effectively controlled inflammation, facilitated corticosteroid tapering, and preserved visual acuity.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"15 1","pages":"27"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909293/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmic Inflammation and Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12348-025-00481-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: We report a case of a 5-year-old patient with Vogt-Koyanagi-Harada presenting atypically with bilateral papillitis and refractory inflammation, leading to uveitic glaucoma and necessitating an escalation of adalimumab to 40 mg biweekly.

Observations: A 5-year-old girl presented with a 3-week history of eye redness, excessive lacrimation, and photophobia. Her medical history was unremarkable. On examination, her best-corrected visual acuity (BCVA) were 20/80 and 20/100 in right and left eye, respectively, with normal intraocular pressure (IOP). Anterior segment examination revealed fine keratic precipitates, anterior chamber inflammation (+ 4 cells and flare), and semi-dilated pupils with posterior synechiae. Posterior segment evaluation was limited by severe vitritis. Laboratory investigations were unremarkable except for HLA-DR4, DR52, and DR53 positivity. Optical coherence tomography (OCT) of the optic nerve showed increased retinal nerve thickness. Initial treatment with corticosteroids and methotrexate failed to achieve remission. Attempts to taper corticosteroids resulted in recurrence of anterior chamber flare, prompting the introduction of adalimumab at 20 mg/biweekly. Despite relative stability, persistent anterior chamber inflammation and subsequent corticosteroid tapering led to the development of uncontrolled uveitic glaucoma requiring surgical peripheral iridectomy. Postoperatively, adalimumab was escalated to 40 mg/biweekly, enabling successful tapering of corticosteroids. Over a 9-month follow-up period, the patient remained flare-free, with BCVA improving to 20/20 in both eyes.

Conclusions and importance: This case highlights an atypical presentation of VKH in a preschool-aged child, characterized by bilateral papillitis without exudative retinal detachment. Escalation of adalimumab to 40 mg biweekly effectively controlled inflammation, facilitated corticosteroid tapering, and preserved visual acuity.

Abstract Image

Abstract Image

一名 5 岁儿童并发 Vogt-Koyanagi-Harada 双侧乳头炎的病例报告。
目的:我们报告了一例5岁的Vogt-Koyanagi-Harada患者,表现为非典型的双侧乳头炎和难治性炎症,导致葡萄膜性青光眼,需要阿达木单抗升级至每两周40mg。观察:一名5岁女孩,有3周的眼部红肿、过度流泪和畏光史。她的病史一般。经检查,其右眼最佳矫正视力(BCVA)为20/80,左眼最佳矫正视力(BCVA)为20/100,眼压正常。前节检查显示有细小的角化沉淀,前房炎症(+ 4细胞和闪光),瞳孔半扩大,后粘连。严重的玻璃体炎限制了后节段的评估。实验室检查除HLA-DR4、DR52和DR53阳性外,无显著差异。视神经光学相干断层扫描显示视网膜神经厚度增加。最初用皮质类固醇和甲氨蝶呤治疗未能达到缓解。试图逐渐减少皮质类固醇导致前房耀斑复发,促使阿达木单抗以20mg /双周剂量引入。尽管相对稳定,但持续的前房炎症和随后的皮质类固醇逐渐减少导致不受控制的葡萄膜性青光眼的发展,需要手术周围虹膜切除术。术后,阿达木单抗升级至40 mg/双周,使皮质类固醇逐渐减量成功。在9个月的随访期间,患者保持无耀斑,双眼BCVA改善至20/20。结论和重要性:本病例强调了学龄前儿童VKH的非典型表现,以双侧乳头炎为特征,无渗出性视网膜脱离。阿达木单抗升级至每两周40毫克,有效控制炎症,促进皮质类固醇逐渐减少,并保持视力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.80
自引率
3.40%
发文量
39
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信